What Is ARA-290 Studied For? Research Areas, Per the Literature

Short answer: what the published literature covers

ARA-290, also written ARA 290 and referred to in clinical literature as cibinetide, is described as a nonerythropoietic peptide engineered from erythropoietin, and it was assessed in a clinical report in patients with type 2 diabetes that looked at metabolic control and neuropathic symptoms (PMID 25387363). Most of the remaining published work sits in animal models and cell based systems covering inflammation, pain signalling, transplantation and organ injury, for example an animal study of cisplatin induced nephrotoxicity that framed ARA290 as a ligand for the erythropoietin/CD131 heteroreceptor (PMID 36085231). ARA-290 is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, including any question about investigational compounds.

Research areas at a glance

The receptor rationale behind the research

The scientific interest in ARA-290 comes from the idea that the tissue protective signalling associated with erythropoietin can be separated from its effect on red blood cell production. A 2013 article in Molecular Medicine discussed erythropoietin receptor agonism and its use across a wide range of disease settings, which is the background against which nonerythropoietic analogues were developed (PMID 23615965). In an animal study of cisplatin induced nephrotoxicity, researchers described ARA290 as a specific ligand for the erythropoietin/CD131 heteroreceptor and examined apoptosis and inflammation pathways as the mechanistic route for the protective effect they reported (PMID 36085231).

Neuropathic symptoms in type 2 diabetes: the main human data point

The most frequently cited human work is a clinical report published in Molecular Medicine in 2015, in which ARA 290 was studied in patients with type 2 diabetes and the study reported improvements in metabolic control and in neuropathic symptoms (PMID 25387363). That publication is a single, small clinical study rather than a programme of large confirmatory trials, so it establishes a research direction rather than a settled clinical conclusion (PMID 25387363). Nothing in the verified literature set compares ARA-290 against established therapies for diabetic neuropathy, and no replication of that clinical finding appears among the papers cited here (PMID 25387363).

Small fiber neuropathy in sarcoidosis

Sarcoidosis associated small fiber neuropathy is the indication most associated with ARA 290 in review literature. A 2014 article in Expert Opinion on Investigational Drugs examined ARA 290 as an investigational agent for the treatment of small fiber neuropathy in sarcoidosis and discussed its development status at that time (PMID 24555851). Separately, a 2017 systematic review in Chronic Respiratory Disease assessed the evidence base for managing fatigue in sarcoidosis, a symptom domain that overlaps with the small fiber neuropathy literature (PMID 27507833). Review coverage of an investigational agent is not the same as regulatory approval, and the 2014 review discussed ARA 290 in an investigational frame (PMID 24555851).

Pain signalling and the TRPV1 channel

A 2016 paper in Peptides reported that ARA 290 relieved pathophysiological pain in experimental models and attributed the effect to actions involving the TRPV1 channel, framing the result as an integration between immune signalling and nociception (PMID 26774587). This is preclinical mechanistic work, so it describes a candidate pathway rather than a clinical outcome in patients (PMID 26774587).

Transplantation and macrophage activation

In a 2016 study published in Transplantation, researchers examined the nonhematopoietic erythropoietin analogue ARA 290 in the context of islet transplantation and reported that it inhibited macrophage activation and prevented damage to transplanted islets (PMID 26683514). The work sits in a preclinical transplantation model, and its relevance is to the immune cell biology of graft injury rather than to any general claim about recovery or repair in healthy people (PMID 26683514).

Chemotherapy related toxicity models

Two papers in the verified set address toxicity caused by cancer drugs. A 2020 in vitro study in Toxicology in Vitro reported that the engineered nonerythropoietic erythropoietin derived peptide ARA290 attenuated doxorubicin induced genotoxicity and oxidative stress in a cell based system (PMID 32335150). A 2023 animal study in Inflammation examined cisplatin induced nephrotoxicity and reported a protective effect linked to apoptosis and inflammation pathways (PMID 36085231). Neither paper is a human oncology trial, and neither establishes that these findings transfer to people receiving chemotherapy (PMID 32335150, PMID 36085231).

Neuroinflammation and Alzheimer-like pathology

A 2022 animal study in Brain, Behavior, and Immunity examined early monocyte modulation by the non-erythropoietic peptide ARA 290 and reported that it decelerated the progression of Alzheimer-like pathology in the model used (PMID 34343617). The emphasis in that work was on peripheral immune cells as an entry point to central nervous system pathology, and the finding is preclinical only (PMID 34343617). No human dementia trial of ARA-290 appears in the verified literature set referenced on this page (PMID 34343617).

ARA-290 as an imaging tool rather than a therapy

One line of work used the peptide as a targeting molecule rather than as a treatment. A 2021 preclinical study in the Iranian Journal of Basic Medical Sciences described the synthesis and evaluation of 99mTc-DOTA-ARA-290 as a potential SPECT tracer for targeting the cardiac ischemic region (PMID 35317117). That study belongs to diagnostic radiochemistry, and it does not report a therapeutic outcome in cardiac disease (PMID 35317117).

Where the evidence is weak, preclinical only or absent

Several uses commonly attached to ARA-290 in general discussion are not supported anywhere in the verified literature set used on this page. There are no studies here on muscle growth, body composition, fat loss, athletic performance, sleep quality, skin appearance, hair, longevity or general wellness. The clinical evidence base is limited to a small study in patients with type 2 diabetes (PMID 25387363) plus review coverage of its investigational use in sarcoidosis associated small fiber neuropathy (PMID 24555851). The remaining research areas listed above are animal, cell based or analytical, for example the mouse neuroinflammation work (PMID 34343617) and the in vitro doxorubicin toxicity work (PMID 32335150). Preclinical results do not predict human outcomes, and effects shown in isolated cells often do not reproduce in whole organisms (PMID 32335150).

Adverse Events and Tolerability: What Studies Report

The verified literature set referenced here contains a single clinical study, which examined ARA 290 in patients with type 2 diabetes and reported outcomes for metabolic control and neuropathic symptoms (PMID 25387363). A clinical research report of that size cannot characterise uncommon or delayed adverse events, and the 2014 investigational drug review of ARA 290 in sarcoidosis discussed the compound while it was still in development rather than as an approved product with a mature safety database (PMID 24555851). Animal and in vitro work such as the islet transplantation study (PMID 26683514) and the cisplatin nephrotoxicity study (PMID 36085231) was designed to test mechanisms in models, not to establish human safety. Long term human safety information for ARA-290 is therefore limited in the published record summarised here (PMID 25387363).

How to read this evidence base

• Count the humans. Only one clinical study in this set reported patient outcomes, and it was conducted in people with type 2 diabetes (PMID 25387363).
• Separate mechanism from outcome. TRPV1 involvement in pain models is a mechanistic observation in preclinical research (PMID 26774587).
• Note the model. A deceleration of AD-like pathology was reported in an animal model, not in people with dementia (PMID 34343617).

Closing note

ARA-290 is not approved by the FDA as a medicine for any condition. This page is not guidance. It summarises what published studies examined and what they reported, so that readers can locate and read the primary sources themselves, including the clinical report in type 2 diabetes (PMID 25387363) and the review of erythropoietin receptor agonism that frames the underlying biology (PMID 23615965). For the broader overview of this peptide, see the hub page at /learn/ara-290/.

References

• ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes (Molecular Medicine, 2015)
• ARA 290 for treatment of small fiber neuropathy in sarcoidosis (Expert Opinion on Investigational Drugs, 2014)
• Managing fatigue in sarcoidosis: a systematic review of the evidence (Chronic Respiratory Disease, 2017)
• Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease (Molecular Medicine, 2013)
• ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: integration between immune system and nociception (Peptides, 2016)
• A nonhematopoietic erythropoietin analogue, ARA 290, inhibits macrophage activation and prevents damage to transplanted islets (Transplantation, 2016)
• An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress (Toxicology in Vitro, 2020)
• Mechanistic approach for protective effect of ARA290, a specific ligand for the erythropoietin/CD131 heteroreceptor, against cisplatin-induced nephrotoxicity (Inflammation, 2023)
• Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression (Brain, Behavior, and Immunity, 2022)
• Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region (Iranian Journal of Basic Medical Sciences, 2021)
• Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry (Journal of Separation Science, 2016)
• Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports (Drug Testing and Analysis, 2017)